Download PDF
Arzneimittelforschung 2010; 60(6): 330-335
DOI: 10.1055/s-0031-1296296
Antibiotics · Antimycotics · Antiparasitics · Antiviral Drugs · Chemotherapeutics · Cytostatics
Editio Cantor Verlag Aulendorf (Germany)

In vitro anti-proliferative effects of the willow bark extract STW 33-I

Gabriel Alejandro Bonaterra
1   Centre for Biomedicine and Biomedical Technology Mannheim (CBTM) University of Heidelberg, Mannheim, Germany
4   Anatomy and Cell Biology, Department of Medical Cell Biology, Marburg, Germany
,
Olaf Kelber
2   Scientific Department, Steigerwald Arzneimittelwerk GmbH, Darmstadt Germany
,
Dieter Weiser
2   Scientific Department, Steigerwald Arzneimittelwerk GmbH, Darmstadt Germany
,
Jürgen Metz
3   Anatomy und Cell Biology III, University of Heidelberg, Heidelberg, Germany
,
Ralf Kinscherf
4   Anatomy and Cell Biology, Department of Medical Cell Biology, Marburg, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
02 December 2011 (online)

    Permissions and Reprints

Abstract

The well-known anti-inflammatory and analgesic effects of the phytopharmacon willow bark extract have been attributed to the content of salicin; however, pharmacological studies have shown that salicin alone, despite being involved in its therapeutic action, cannot fully explain its clinical efficacy. In addition to reducing inflammation and pain, acetylsalicylic acid (ASA, CAS 50-78-2), like other synthetic non-steroidal anti-inflammatory drugs (NSAIDs), has been shown to exert anti-proliferative effects and to induce apoptosis in a variety of cell lines, e. g. colon, stomach, and prostate cancer cells. To investigate the mechanism of action and possible anti-proliferative and pro-apoptotic effects of willow bark, a water extract (STW 33-1) and a polyphenol rich fraction (fraction E) have been tested by using the colon-carcinoma cell line HT-29. Both, STW 33-1 and its fraction E showed significant anti-proliferative and pro-apoptotic effects on HT-29 cancer cells. Related to the salicin content of the willow bark extract, a higher dosage of ASA was needed. Furthermore, compared to ASA and to diclofenac (Diclo, CAS 15307-79-6), the COX-1 and COX-2 mRNA expressions were influenced differently by STW 33-1 and fraction E. ASA and Diclo inhibited both the COX-1 and COX-2 mRNA expressions, whereas STW 33-1 and its fraction E increased the COX-1 mRNA expression.

In addition to the already well-known anti-inflammatory and analgesic effects, willow bark extract has been found to possess anti-proliferative and pro-apoptotic effects similar to NSAIDs. The different influence of willow bark on the COX-1 and COX-2 mRNA expressions in comparison to NSAIDs might be relevant, e. g. for prevention of undesirable side effects such as gastric erosions.

Key words

Apoptosis - Colon carcinoma - Cyclooxygenase - Non-steroidal anti-inflammatory drugs - STW 33-1 - Willow bark extract
 

  • References

  • 1 Nahrstedt A, Schmidt M, Jäggi R, Metz J, Khayyal MT. Willow bark extract: The contribution of polyphenols to the overall effect. Wien Med Wochenschr. 2007; 157 (13–14) 348-51
    CrossrefPubMedGoogle Scholar
  • 2 Fiebich BL, Klin J, Zeller K, Weiser D. Antiinflammatory effects of Salix: Salix extracts as inhibitors of the expression and synthesis of cytokines, matrix-metalloproteases, prostaglandins and COX-2 in LPS-treated primary human monocytes and chrondrocytes. Osteoarthritis Cartilage. 2003; 11: S119-P332
    PubMedGoogle Scholar
  • 3 Kelber O, Bonaterra GA, Kinscherf R, Weiser D, Metz J. Inhibitorische Effekte von Weidenrindenextrakten auf proinflammatorische Prozesse in LPS-aktivierten Humanmonozyten. Z Rheumatol. 2006; 65 (1) S31
    PubMedGoogle Scholar
  • 4 Bonaterra GA, Kinscherf R, Kelber O, Weiser D, Metz J. Antiinflammatorische und antiproliferative Wirkung von Iberogast in vitro. Z Gastroenterol. 2008; 46: 1038-9
    PubMedGoogle Scholar
  • 5 Wuthold K, Germann I, Roos G, Kelber O, Weiser D, Heinle H et al Thin-layer chromatography and multivariate data analysis of willow bark extracts. J Chromatogr Sci. 2004; 42 (6) 306-9
    PubMedGoogle Scholar
  • 6 Khayyal MT, El-Ghazaly MA, Abdallah DM, Okpanyi SN, Kelber O, Weiser D. Mechanisms involved in the anti-inflammatory effect of a standardized willow bark extract. Arzneimittelforschung. 2005; 55 (11) 677-87
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Lardos A, Schmidlin CB, Fischer M, Ferlas-Chlodny E, Lo-niewski I, Samochoviec L et al Wirksamkeit und Verträglichkeit eines wässrig ausgezogenen Weidenrindenextrak-tes bei Patienten mit Hüft- und Kniearthrose. Z Phytother. 2004; 25: 275-81
    PubMedGoogle Scholar
  • 8 Kähkönen MP, Hopia AI, Vuorela HJ, RauhaJPPihlaja K, Kujala TS et al Antioxidant Activity of Plant Extracts Containing Phenolic Compounds. J Agric Food Chem. 1999; 47 (10) 3954-62
    CrossrefPubMedGoogle Scholar
  • 9 Mahdi JG, Mahdi AJ, Mahdi AJ, Bowen ID. The historical analysis of aspirin discovery, its relation to the willow tree and antiproliferative and anticancer potential. Cell Prolif. 2006; 39: 147-55
    CrossrefPubMedGoogle Scholar
  • 10 Hostanska K, Jürgenliemk G, Abel G, Nahrstedt A, Saller R. Willow bark extract (BNO1455) and its fractions suppress growth and induce apoptosis in human colon and lung cancer cells. Cancer Detect Prev. 2007; 31 (2) 129-39
    CrossrefPubMedGoogle Scholar
  • 11 Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest. 1995; 96: 491-503
    CrossrefPubMedGoogle Scholar
  • 12 Lazzaroni M, Bianchi Porro G. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment Pharmacol Ther. 2004; 20 (2) 48-58
    PubMedGoogle Scholar
  • 13 Kim JS, Baek SJ, Sali T, Elig TE. The conventional nonsteroidal ant-inflammatory drug sulindac sulfide arrest ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol Cancer Ther. 2005; 4: 487-93
    PubMedGoogle Scholar
  • 14 Erickson BA, Longo WE, Panesar N, Mazuski JE, Kaminski DL. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res. 1999; 81: 101-7
    CrossrefPubMedGoogle Scholar
  • 15 Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor in rheumatoid synovial cells. J Pharmacol Exp Ther. 2002; 302: 18-25
    CrossrefPubMedGoogle Scholar
  • 16 Rupnarain C, Dlamini Z, Naicker S, Bhoola K. Colon cancer: genomics and apoptotic events. Biol Chem. 2004; 385: 449-64
    CrossrefPubMedGoogle Scholar
  • 17 Tegeder I, Pfeilschifter J, Geisslingerl G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001; 15: 2057-72
    CrossrefPubMedGoogle Scholar
  • 18 Fridrich D, Kern M, Pahlke G, Volz N, Will F, Dietrich H et al Apple polyphenols diminish the phosphorylation of the epidermal growth factor receptor in HT29 colon carcinoma cells. Mol Nutr Food Res. 2007; 51: 594-601
    CrossrefPubMedGoogle Scholar
  • 19 Idziorek T, Estaquier J, De Bels F, Ameisen J-C. YOPRO-1 permits cytofluorometric analysis of programmed cell death (apoptosis) without interfering with cell viability. J Immunol Methods. 1995; 185: 249-58
    CrossrefPubMedGoogle Scholar
  • 20 Deigner HP, Claus R, Bonaterra GA, Gehrke C, Bibak N, Blaess M et al Ceramide induces aSMase expression: implications for oxLDL-induced apoptosis. FASEB J. 2001; 15: 807-14
    CrossrefPubMedGoogle Scholar
  • 21 Kinscherf R, Wagner M, Kamencic H, Bonaterra GA, Hou D, Schiele RA et al Characterization of apoptotic macrophages in atheromatous tissue of humans and heritable hyperlipidemic rabbits. Atherosclerosis. 1999; 144: 33-9
    PubMedGoogle Scholar
  • 22 Ganguly T, Khar A. Induction of apoptosis in a human ery-throleukemic cell line K562 by tylophora alkaloids involves release of cytochrome c and activation of caspase-3. Phyto-medicine. 2002; 9: 288-95
    CrossrefPubMedGoogle Scholar
  • 23 Subbegowda R, Frommel TO. Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest. Cancer Res. 1998; 58: 2772-6
    PubMedGoogle Scholar
  • 24 Calatayud C, Warner TD, Breese EJ, Mitchell JA. Relationship between endogenous colony stimulating factors and apoptosis in human colon cancer cells: role of cyclo-oxygenase inhibitors. Br J Pharmacol. 2001; 134: 1237-44
    CrossrefPubMedGoogle Scholar
  • 25 Elder DJ, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-innflammatory drug: independence from COX-2 protein expression. Clin Cancer Res. 1997; 3: 1679-83
    PubMedGoogle Scholar
  • 26 Shiff SJ, Rigas B. Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology. 1997; 113: 1992-8
    CrossrefPubMedGoogle Scholar
  • 27 Chell S, Patsos HA, Qualtrough D, H-Zadeh AM, Hicks DJ, Kaidi A et al Prospects in NSAID-derived chemoprevention of colorectal cancer. Biochem Soc Trans. 2005; 33: 667-71
    CrossrefPubMedGoogle Scholar
  • 28 Sample D, Wargovich M, Fischer SM, Inamdar N, Schwartz P, Wang X et al A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev. 2002; 11: 275-9
    PubMedGoogle Scholar
  • 29 Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L et al Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin- independent pathway. Biochem Pharmacol. 1996; 52: 237-45
    CrossrefPubMedGoogle Scholar
  • 30 Kuntz S, Wenzel U, Daniel H. Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur J Nutr. 1999; 38: 133-42
    CrossrefPubMedGoogle Scholar
  • 31 Hotz-Behofsits CM, Walley MJ, Simpson R, Bjamason IT. COX-1, COX-2 and the topical effect in NSAID-induced enteropathy. Inflammopharmacology. 2003; 11 (4–6) 363-70
    CrossrefPubMedGoogle Scholar
  • 32 Sales KJ, Katz AA, Howard B, Soeters RP, Millar RP, Jabbour HN. Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin E receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res. 2002; 62: 424-32
    PubMedGoogle Scholar
  • 33 Parrentti L, Perretti M. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol. 2003; 65 (2) 153-9
    CrossrefPubMedGoogle Scholar
  • 34 Church RD, Yu J, Fleshman JW, Shannon WD, Govindan R, McLeod HL. RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer. Br J Cancer. 2004; 91 (6) 1015-8
    PubMedGoogle Scholar
  • 35 Zidar N, Odar K, Glavač D, Jerše M, Zupanc T, Stajer D. Cyclooxygenase in normal human tissues - is COX-1 really a constitutive isoform, and COX-2 an inducible isoform?. J Cell Mol Med. 2008; 13 (9b) 3753-63 Epub 2008 Jul 24.
    PubMedGoogle Scholar
  • 36 Li Q, Withoff S, Verma IM. Inflammation-associated cancer: NF-kB is the lynchpin. Trends Immunol. 2005; 26: 318-25
    CrossrefPubMedGoogle Scholar